Navigation Links
Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
Date:4/4/2011

iation for Cancer Research (www.aacr.org) being held in Orlando, FL from April 2 through April 6.  That study, entitled "Circulating regulatory T cells (CD4+CD25[high] CD127[low]) decrease in breast cancer patients after vaccination with a modified HER-2/neu HLA class II peptide (AE37) vaccine", will be presented April 5.  The study shows that a subgroup of CD4+ cells that have the potential to suppress immune responses, termed T regulatory cells, actually decrease after immunization with AE37.  This decrease in T regulatory cells was not observed in patients immunized with GP2.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of c
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Generex Announces $3.0 Million Capital Investment
2. Generex Provides Additional Details for October 21st Live Video Webcast
3. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
4. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
7. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
8. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. Techne Corporation Announces Acquisition
11. Life Technologies Announces Launch of 2010 Online Annual Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... 23, 2013  Rahal Letterman Lanigan Racing (RLL) and ... stem cell banking and therapeutics, announced today that StemCyte ... Acorn Stairlifts Indy car driven by James ... the IZOD IndyCar 2013 season.   StemCyte, ... support awareness of umbilical cord blood banking and its ...
(Date:5/23/2013)... Calif. , May 23, 2013 Virobay, ... treatment for pain has reached an important milestone, as ... of VBY-036 - a selective cathepsin S inhibitor.   ... is a double-blind, randomized, placebo-controlled study designed to evaluate ... of VBY-036 in healthy adults. "The initiation ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... GenVault,s energy and space efficient technologies ideally suit ... create a new paradigm for eco-friendly, sustainable Biobanking ... announces the opening of its newly-formed Japanese subsidiary ... the expanding Biobanking market and its growing customer ...
... Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today ... ophthalmic gel, 0.15%, has been accepted for review by ... is seeking approval for ganciclovir as a treatment for ... simplex virus. The FDA has issued an action date ...
... 26 Fifty percent of clinical trial management ... share high-value, proprietary company information via e-mail, while ... overnight courier (14 percent), according to a recent ... for exchanging clinical trial information with outside parties ...
Cached Biology Technology:GenVault Opens Japanese Subsidiary to Better Address Global Biobanking Market Growth 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3IntraLinks Poll: Half of Clinical Trial Management Professionals Share Critical Information Via E-Mail 2
(Date:5/24/2013)... systems like ecosystems can get messy, especially when trying ... like climate change. , In a new paper ... of the National Academy of Sciences , researchers from ... assumption at the very heart of a popular way ... how climate changes may impact biodiversity, researchers like Jessica ...
(Date:5/24/2013)... 24, 2013 A frequently expressed concern in the ongoing ... fresh vegetables, especially those that are nutrient dense. ... and Beans Provide Most Nutrients Per Penny," published in ... are one of the best nutritional values in the ... per penny than most other raw vegetables and delivering ...
(Date:5/24/2013)... fastest growing open-access publishers, today announces the launch of ... A broad scope journal covering all specialties, Frontiers ... web platform for the research community to publish high ... and interactive peer-review enables fast, fair and constructive review ... of three months from submission to final decision for ...
Breaking Biology News(10 mins):Understanding the past and predicting the future by looking across space and time 2New research shows that potatoes provide one of the best nutritional values per penny 2Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3
... clumps of protein found within nerve cells are ... were first identified in the early 1900s by German ... in a protein called tau cause it to aggregate ... Normally, the tau protein is involved in the formation ...
... of cardiovascular disease, research from the Sahlgrenska Academy at the ... obesity hormones adiponectin - are also linked to osteoporosis ... is more than just bones, vertebrae and joints. In fact, ... our brain, our muscles and our fatty tissue. Stem cells ...
... D deficiency is common in Americans, and especially in ... of Health. University of Missouri researchers have found that ... vitamin D3 is safe and effective in improving their ... risk for deficiency because they tend to absorb vitamin ...
Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Obese adolescents benefit from high-dose vitamin D supplements 2
Human sIL-2R/CD25 ELI-PAIR Kit...
Request Info...
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Biology Products: